SAGA Diagnostics appoints Peter Collins as Chief Executive Officer

LUND, Sweden — /October 7, 2021/ — SAGA Diagnostics AB, (“SAGA”), a leading cancer liquid biopsy and genomic testing company, is pleased to announce the appointment of Peter Collins as Chief Executive Officer.

 

Mr. Collins is a highly experienced entrepreneur with over 30 years of experience in the pharma and diagnostics sector.

He joins SAGA after successful executive roles at major players in the liquid biopsy field such as Inivata as Chief Business Officer and at Guardant Health as VP Biopharma Business Development, and CBO of Yourgene. Peter was also VP, Head of Diagnostics at GSK for 5 years. Throughout his various executive positions, he has demonstrated a track record of building high performance teams and leading organizations’ commercial growth.

 

 

 

SAGA is an outstanding company with a leading technology and solid market traction. Ultrasensitivity and detection of minimal residual disease (MRD) is exactly what biopharma, the clinical testing market and cancer patients need. SAGA has a diverse and exceptionally talented team already in place – I’m excited to lead this next phase of growth, build out the team further, and execute on a strategy to rapidly bring our technologies into the clinics to benefit more people living with cancer.
Peter Collins, CEO of SAGA Diagnostics

 

We are delighted to welcome Peter to the SAGA team as our new CEO. With his highly relevant, results-driven experience and extensive network, we are confident that Peter will lead the company in its next phase of growth to becoming one of the leaders in cancer liquid biopsy testing and genomic profiling.
Greg Batchellor, Chairman of SAGA Diagnostics

 

Founding CEO Dr. Lao Saal has been appointed Chief Operating Officer and remains a member of the Board of Directors.

 

We are delighted to welcome Peter to the SAGA team as our new CEO. I have enjoyed leading SAGA these last 5+ years, and Peter is exactly the right person to receive the reins for this next stage of growth. In my new role as COO, I will be supporting Peter, the wider SAGA team and our Board to deliver on our vision to make SAGA’s technologies available to as many cancer patients as possible and truly make a difference to people’s lives.
Lao Saal, COO and Co-Founder of SAGA Diagnostics

 


 

Contact:

CEO Peter Collins  media@sagadiagnostics.com  Phone: +46 (0) 733 01 7242

Media:

Richard Hayhurst/Ola Björkman  richard@rhapr.eu  Phone: +44 (0) 7711 821527

 

About SAGA Diagnostics AB
SAGA Diagnostics is a personalized cancer genomics and disease monitoring company that offers molecular genetic testing of tissue biopsies and non-invasive “liquid biopsies” such as blood samples. SAGA helps pharmaceutical companies, scientists, and healthcare providers to detect actionable mutations, stratify patient groups, and monitor treatment response more accurately and to an industry-leading lower limit of detection of 0.001%. Analysis of circulating tumor DNA using its proprietary technologies gives SAGA unique ultrasensitivity, and provides the basis for optimal decision-making.

Follow SAGA on Twitter @SAGAdiagnostics and LinkedIn.